



For more information go to: www.neuroaid.com or Email: medical@moleac.com

References

1. Heurteaux C, et al. Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. *Neuropharmacology* 2010; 58:987-1001.
2. Gandin C, et al. MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice. *Cerebrovasc Dis* 2016; 42:139-154.
3. Moha Ou Maati H, et al. Activation of ATP sensitive potassium channels as an element of the neuroprotective effects of the traditional Chinese medicine MLC901 against oxygen glucose deprivation. *Neuropharmacology* 2012; 63:692-700.
4. Venketasubramanian N, et al. Chinese Medicine NeuroAid Efficacy on Stroke recovery – Extension Study (CHIMES-E): A multicenter study of long-term efficacy. *Cerebrovascular Diseases* 2015; 39:309-318.
5. Venketasubramanian N, et al. Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAid™) in the Chinese Medicine NeuroAid Efficacy on Stroke Recovery – Extension Study. *Cerebrovascular Diseases* 2017; 43:36-42.
6. Suwanwela NC, et al. Effect of Combined Treatment with MLC601 (NeuroAid™) and Rehabilitation on Post-Stroke Recovery: The CHIMES and CHIMES-E Studies. *Cerebrovasc Dis* 2018 doi: 10.1159/000492625.
7. Harandi AA, et al. Safety and efficacy of MLC601 in Iranian patients after stroke: a double-blind, placebo-controlled clinical trial. *Stroke Research and Treatment* 2011; doi:10.4061/2011/721613.
8. Chen C, et al. Effects of MLC601 on early vascular events in patients after stroke: The CHIMES study. *Stroke* 2013b; 44:3580-3583.
9. Theadom A, Barker-Collo S, Jones KM, Parmar P, Bhattacharjee R, Feigin VL. MLC901 (NeuroAid II™) for cognition after traumatic brain injury: A pilot randomised clinical trial. *Eur J Neurol*. 2018 doi:10.1111/ene.13653



Moleac Pte Ltd

11 Biopolis Way, Helios Building #09-08, Singapore 138667 Tel: +65 6211 3710 • Fax: +65 6478 9435

NurAid™ is a trademark of Moleac. MLC601 (NeuroAid™) and MLC901 (NeuroAid™II / NurAid™II) are 2 different proprietary formulae which have been shown to be equivalent in pharmacology. and are referred to as «NurAid™II» in this document.

NurAid for post stroke recovery

Amplification of brain self-repair processes translating into persistent functional recovery

- ▶ ~50% increase in odds of achieving functional independence at 6 months
- ▶ Persistent recovery for up to 2 years
- ▶ Double the odds of achieving functional independence when combined with Rehabilitation compared to Rehabilitation alone
- ▶ Improvement of motor recovery as early as 1 month of treatment and at each time point

Patient Recommendations

Adult patients suffering from neurological deficits following a stroke or a traumatic brain injury (TBI).

- ▶ **For post-stroke patients**
Initiate NurAid once the patient is stabilized at the post-acute phase, and up to 6 months post stroke onset.
- ▶ **For post-Traumatic Brain Injury patients⁹**
Initiate NurAid from 1 month and up to 1 year after the TBI.

Administration

2 CAPSULES, **3** TIMES/DAY, FOR **3** MONTHS

Composition

NurAid™II is made of 9 herbal ingredients:

Radix Astragali, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Radix Polygalae, Rhizoma Chuanxiong, Rhizoma Acori Tatarinowii, Semen Persicae, Carthami Flos.

Precautions

To date, no drug interaction has been reported. Not recommended for lactating or pregnant women. No data of use in children. Rare and transient adverse events may include gastro-intestinal disturbance, nausea, vomiting.



EVIDENCE IN POST STROKE RECOVERY

**Persistent improvement
2 years follow up**



GM-ST-0514-V1-2019

Amplification of brain self-repair processes^{1,2,3}


NurAiD: a multimodal mode of action

Stroke recovery involves multiple pharmacological pathways, each contributing to neurorepair. With its multimodal properties, NurAiD amplifies multiple mechanisms which act synergistically to boost Neurorepair. These translate into persistent functional recovery in patients.


NurAiD Promotes Neurorepair

Stimulates Growth Factors

- ▶ Brain Derived Neurotrophic Factor (BDNF)
- ▶ Vascular Endothelial Growth Factor (VEGF)




Epifluorescence microscopy of BDNF immuno-expression in cortical neurons in brain sections pre-treated with NurAiD



Epifluorescence microscopy of a double-labelled BrdU/NeuN cells after 3 weeks in mice with 6 weeks treatment and BrdU injection

Promotes Neurogenesis

- ▶ Increases the number of new functional neuronal cells



Epifluorescence microscopy of DCX protein expression in neuronal cells cultures at 14 days

Amplifies Neuroplasticity

- ▶ Boosts connectivity by promoting neurite outgrowth and synaptogenesis

NurAiD protects against neuronal damages

- ▶ Activates ATP-dependent K⁺ channels contributing to neuroprotection and ischemic preconditioning
- ▶ Improves neurons viability, reduces infarct size and oxidative stress

Persistent functional recovery^{4,5}


Capturing full treatment value requires assessment >3 months

The timing for the outcome should maximize the observation of a potential benefit between the tested therapy and the standard of care. It is well established that some patients continue to improve six months post stroke while many others tend to deteriorate and lose improvements gained initially. As such, **full treatment value is only captured at 12 to 24 months.**

The CHIMES-E Study, assessing recovery over 2 years

- ▶ Preplanned study on 880 subjects with Acute Ischemic Stroke followed up for 2 years
- ▶ Randomized to 3 months of either NurAiD or placebo

Odds of achieving functioning independence (mRS 0-1)




+50% in odds of achieving functional independence at 6 months

- ▶ Persistent recovery **demonstrates treatment value over time**
- ▶ **More patients reaching independence** in NurAiD group up to 2 years
- ▶ **Less patients deteriorating** over time in NurAiD group versus placebo
- ▶ **Excellent safety profile**, and no delayed serious adverse event up to 2 years

Combining NurAiD and Rehabilitation doubles the odds of achieving functional independence versus Rehabilitation alone⁶

Success rates (%) of achieving functional independence (mRS <= 1)




- ▶ **Statistically significant odds ratio at all time points** from 3 months to 2 years from stroke onset
- ▶ Persistent recovery with benefits sustained for up to 2 years
- ▶ Numbers Needed to Treat: **NNT range from 5 to 7**

NurAiD improves motor recovery⁷

In post-acute stroke patients with upper and lower limbs deficits:

- ▶ Subjects included up to one month following an ischemic stroke (n=150)
- ▶ **Significantly better motor recovery**



NurAiD prevents early vascular events⁸

- ▶ **50% reduction in occurrence of early vascular events** (i.e. recurrent stroke, acute coronary event, vascular death)
- ▶ Added value to ensure optimal condition for a stable recovery process



EVIDENCE IN POST STROKE RECOVERY

**Persistent improvement
2 years follow up**



Amplification of brain self-repair processes^{1,2,3}


NurAiD: a multimodal mode of action

Stroke recovery involves multiple pharmacological pathways, each contributing to neurorepair. With its multimodal properties, NurAiD amplifies multiple mechanisms which act synergistically to boost Neurorepair. These translate into persistent functional recovery in patients.

NurAiD Promotes Neurorepair

Stimulates Growth Factors


- ▶ Brain Derived Neurotrophic Factor (BDNF)
- ▶ Vascular Endothelial Growth Factor (VEGF)



Epifluorescence microscopy of a double-labelled BrdU/NeuN cells after 3 weeks in mice with 6 weeks treatment and BrdU injection

Amplifies Neuroplasticity


- ▶ Boosts connectivity by promoting neurite outgrowth and synaptogenesis



Epifluorescence microscopy of BDNF immuno-expression in cortical neurons in brain sections pre-treated with NurAiD

Promotes Neurogenesis

- ▶ Increases the number of new functional neuronal cells



Epifluorescence microscopy of DCX protein expression in neuronal cells cultures at 14 days

NurAiD protects against neuronal damages

- ▶ Activates ATP-dependent K⁺ channels contributing to neuroprotection and ischemic preconditioning
- ▶ Improves neurons viability, reduces infarct size and oxidative stress

Persistent functional recovery^{4,5}


Capturing full treatment value requires assessment >3 months

The timing for the outcome should maximize the observation of a potential benefit between the tested therapy and the standard of care. It is well established that some patients continue to improve six months post stroke while many others tend to deteriorate and lose improvements gained initially. As such, **full treatment value is only captured at 12 to 24 months.**

The CHIMES-E Study, assessing recovery over 2 years

- ▶ Preplanned study on 880 subjects with Acute Ischemic Stroke followed up for 2 years
- ▶ Randomized to 3 months of either NurAiD or placebo

Odds of achieving functioning independence (mRS 0-1)




+50% in odds of achieving functional independence at 6 months

- ▶ Persistent recovery **demonstrates treatment value over time**
- ▶ **More patients reaching independence** in NurAiD group up to 2 years
- ▶ **Less patients deteriorating** over time in NurAiD group versus placebo
- ▶ **Excellent safety profile**, and no delayed serious adverse event up to 2 years

Combining NurAiD and Rehabilitation doubles the odds of achieving functional independence versus Rehabilitation alone⁶

Success rates (%) of achieving functional independence (mRS ≤ 1)




- ▶ **Statistically significant odds ratio at all time points** from 3 months to 2 years from stroke onset
- ▶ Persistent recovery with benefits sustained for up to 2 years
- ▶ Numbers Needed to Treat: **NNT range from 5 to 7**

NurAiD improves motor recovery⁷

In post-acute stroke patients with upper and lower limbs deficits:

- ▶ Subjects included up to one month following an ischemic stroke (n=150)
- ▶ **Significantly better motor recovery**



NurAiD prevents early vascular events⁸

- ▶ **50% reduction in occurrence of early vascular events** (i.e. recurrent stroke, acute coronary event, vascular death)
- ▶ Added value to ensure optimal condition for a stable recovery process



For more information go to: www.neuroaid.com or Email: medical@moleac.com

References

1. Heurteaux C, et al. Neuroprotective and neuroproliferative activities of NeuroAiD (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. *Neuropharmacology* 2010; 58:987-1001.
2. Gandin C, et al. MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice. *Cerebrovasc Dis* 2016; 42:139–154.
3. Moha Ou Maati H, et al. Activation of ATP sensitive potassium channels as an element of the neuroprotective effects of the traditional Chinese medicine MLC901 against oxygen glucose deprivation. *Neuropharmacology* 2012; 63:692-700.
4. Venketasubramanian N, et al. CHInese Medicine NeuroAiD Efficacy on Stroke recovery – Extension Study (CHIMES-E): A multicenter study of long-term efficacy. *Cerebrovascular Diseases* 2015; 39:309-318.
5. Venketasubramanian N, et al. Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study. *Cerebrovascular Diseases* 2017; 43:36–42.
6. Suwanwela NC, et al. Effect of Combined Treatment with MLC601 (NeuroAiDTM) and Rehabilitation on Post-Stroke Recovery: The CHIMES and CHIMES-E Studies. *Cerebrovasc Dis* 2018 doi: 10.1159/000492625.
7. Harandi AA, et al. Safety and efficacy of MLC601 in Iranian patients after stroke: a double-blind, placebo-controlled clinical trial. *Stroke Research and Treatment* 2011; doi:10.4061/2011/721613.
8. Chen C, et al. Effects of MLC601 on early vascular events in patients after stroke: The CHIMES study. *Stroke* 2013b; 44:3580-3583.
9. Theadom A, Barker-Collo S, Jones KM, Parmar P, Bhattacharjee R, Feigin VL. MLC901 (NeuroAid II™) for cognition after traumatic brain injury: A pilot randomised clinical trial. *Eur J Neurol*. 2018 doi:10.1111/ene.13653



Moleac Pte Ltd

11 Biopolis Way, Helios Building #09-08, Singapore 138667 Tel: +65 6211 3710 • Fax: +65 6478 9435

NurAid™ is a trademark of Moleac. MLC601 (NeuroAiD™) and MLC901 (NeuroAiD™II / NurAid™II) are 2 different proprietary formulae which have been shown to be equivalent in pharmacology. and are referred to as «NurAid™II» in this document.

NurAiD for post stroke recovery

Amplification of brain self-repair processes translating into persistent functional recovery

- ▶ ~50% increase in odds of achieving functional independence at 6 months
- ▶ Persistent recovery for up to 2 years
- ▶ Double the odds of achieving functional independence when combined with Rehabilitation compared to Rehabilitation alone
- ▶ Improvement of motor recovery as early as 1 month of treatment and at each time point

Patient Recommendations

Adult patients suffering from neurological deficits following a stroke or a traumatic brain injury (TBI).

▶ For post-stroke patients

Initiate NurAiD once the patient is stabilized at the post-acute phase, and up to 6 months post stroke onset.

▶ For post-Traumatic Brain Injury patients⁹

Initiate NurAiD from 1 month and up to 1 year after the TBI.

Administration

2 CAPSULES, **3** TIMES/DAY, FOR **3** MONTHS

Composition

NurAiD™II is made of 9 herbal ingredients:

Radix Astragali, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Radix Polygalae, Rhizoma Chuanxiong, Rhizoma Acori Tatarinowii, Semen Persicae, Carthami Flos.

Precautions

To date, no drug interaction has been reported. Not recommended for lactating or pregnant women. No data of use in children. Rare and transient adverse events may include gastro-intestinal disturbance, nausea, vomiting.